Evidence map›Paper›PMID 32785799›Full record

Trial reportInternational journal of clinical oncology2020

Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan.

Ryo Ohta, Takeshi Yamada, Keisuke Hara, Takuma Iwai, Kohji Tanakaya, Keiichiro Ishibashi, Kazuhiko Yoshimatsu, Chihiro Kosugi, Masahiro Tsubaki, Hideo Nakajima and 4 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Ryo OhtaDepartment of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Takeshi YamadaDepartment of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan. y-tak@nms.ac.jp.ORCID http://orcid.org/0000-0002-1436-7482
Keisuke HaraDepartment of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Takuma IwaiDepartment of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Kohji TanakayaDepartment of Surgery, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan.
Keiichiro IshibashiDepartment of Surgery Saitama Medical center, Saitama Medical University, Saitama, Japan.
Kazuhiko YoshimatsuDepartment of Surgery, Tokyo Women's Medical University, Medical Center East, Tokyo, Japan.
Chihiro KosugiDepartment of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan.
Masahiro TsubakiDepartment of Surgery, Yuai Memorial Hospital, Koga, Japan.
Hideo NakajimaDepartment of Oncology, Ageo Central General Hospital, Ageo, Japan.
Masatoshi OyaDepartment of Surgery Saitama Medical center, Dokkyo University School of Medicine, Mibu, Japan.
Hiroshi YoshidaDepartment of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Keiji KodaDepartment of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan.
Hideyuki IshidaDepartment of Surgery Saitama Medical center, Saitama Medical University, Saitama, Japan.
Nippon Medical School · JPSaitama Medical University · JPTeikyo University Chiba Medical Center · JPDokkyo University · JPHakodate Central General Hospital · JPIwakuni Medical Center · JPTokyo Women's Medical University Adachi Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemotherapy with oxaliplatin is known to induce sinusoidal obstruction syndrome (SOS). In a previous single-center study, we reported that oxaliplatin-induced increase in splenic volume (SV) is strongly indicative of SOS, and that this increase in SV persisted for > 1 year after completing chemotherapy. The aim of this study was to confirm the oxaliplatin-induced SV change in a multicenter study in patients with stage III colon cancer in Japan.

methodsWe enrolled 59 patients who underwent curative resection for stage III colon cancer in the FACOS study in a phase II multi-center clinical study. Participants received mFOLFOX6 or CAPOX as adjuvant chemotherapy. SV change was assessed three times by computed tomographic volumetry: before surgery, on completion of adjuvant chemotherapy, and 1 year after completing adjuvant chemotherapy.

resultsSV on completing and 1 year after chemotherapy was significantly higher than that before surgery (P < 0.001). Oxaliplatin-induced SOS persisted for > 1 year after the completion of adjuvant chemotherapy in half of the patients. There was no difference in 3-year disease-free survival with respect to the presence or absence of increased SV. An increase in SV was observed in 72% of patients treated with mFOLFOX6 and 94% of patients treated with CAPOX (P = 0.13).

conclusionThis study can be verified the findings observed in our previous single-center study, oxaliplatin-based adjuvant chemotherapy was associated with an increase in SV. Furthermore, this increase can persist for > 1 year. The continuous presence of SOS may have a negative impact on prognosis in patients that develop recurrent disease.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColonic NeoplasmsDisease-Free SurvivalFemaleFluorouracilHumansJapanLeucovorinMaleMiddle AgedOrganoplatinum CompoundsOxaliplatinPrognosisSplenic DiseasesFluorouracilLeucovorinOrganoplatinum CompoundsOxaliplatinColorectal cancerOxaliplatinSinusoidal obstruction syndromeSplenic volume

Identifiers

PMID32785799
OpenAlexW3048373534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.